# An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)

> **NCT00132730** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 604 (actual)

## Conditions studied

- Lung Diseases
- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** MK-0873 2.5 mg
- **DRUG:** MK-0873 1.25 mg
- **DRUG:** MK-0873 0.75 mg
- **DRUG:** Placebo to MK-0873
- **DRUG:** Usual Care

## Key facts

- **NCT ID:** NCT00132730
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-06-01
- **Primary completion:** 2005-08-17
- **Final completion:** 2005-08-17
- **Target enrollment:** 604 (ACTUAL)
- **Last updated:** 2018-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00132730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00132730, "An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00132730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*